Inventiva

IVAPhase 3

Inventiva is a public biopharma company (Euronext: IVA) focused on discovering and developing oral small molecule therapies for significant unmet needs in fibrosis, lysosomal diseases, and oncology. Its core asset is lanifibranor, a unique pan-PPAR agonist in a pivotal global Phase 3 trial (NATiV3) for NASH/MASH, with topline results expected in H2 2026. The company's strategy is built on a robust discovery platform, a deep chemistry library, and key partnerships, positioning it as a potential leader in the evolving NASH treatment landscape.

Market Cap

$1.2B

Employees

80-100

Focus

Small Molecules

IVA · Stock Price

USD 5.785.32 (-47.93%)

Historical price data

AI Company Overview

Technology Platform

A proprietary drug discovery platform specializing in nuclear receptors, transcription factors, and epigenetic modulation, supported by an in-house chemical library of 240,000 molecules and a team of ~80 scientists.

Pipeline Snapshot

7 drugs in pipeline, 1 in Phase 3

Drug	Indication	Stage
IVA337 + Placebo	NASH - Nonalcoholic Steatohepatitis	Phase 3
IVA337 + Placebo	Scleroderma, Diffuse	Phase 2
Odiparcil	Mucopolysaccharidosis VI	Phase 2
IVA337 + IVA337 + Placebo	Non-Alcoholic Steatohepatitis (NASH)	Phase 2
IVA337 + Placebo + Empagliflozin	NASH - Nonalcoholic Steatohepatitis	Phase 2

Funding History

Total raised: $50M

PIPE$50MSofinnova PartnersJun 15, 2021

IPOUndisclosedUndisclosedJul 15, 2017

Opportunities

The primary opportunity is launching the first-in-class pan-PPAR agonist for the vast, treatment-naive NASH/MASH market, projected to be multi-billion dollar.

Success could also validate the company's platform, enabling expansion into other fibrotic, metabolic, and lysosomal diseases.

Existing partnerships provide a foundation for ex-European market access.

Risk Factors

High clinical risk from the ongoing Phase 3 trial (NATiV3), with binary outcomes expected in H2 2026.

Intense competition in NASH from other late-stage candidates.

Financial risk as a pre-revenue company funding an expensive global trial.

Pipeline concentration risk on a single lead asset.

Competitive Landscape

Competes in the crowded NASH space against companies like Madrigal, 89bio, and Akero. Lanifibranor's key differentiation is its unique pan-PPAR mechanism, designed to comprehensively address steatosis, inflammation, and fibrosis. Its oral administration and FDA Breakthrough Therapy designation are competitive advantages, but it must demonstrate superior or differentiated efficacy/safety to capture market share.

Publications

Pipeline